SABC San Antonio Breast Cancer Symposium 2021
SOFT/TEXT trial updates
Meredith Regan, ScD presented an update on the SOFT/TEXT clinical trials at the 2021 San Antonio Breast Cancer Symposium.

Press Release
For premenopausal women with breast cancer, ovarian suppression provides greater reduction in long-term risk of recurrence than tamoxifen alone, researchers find

For premenopausal women with hormone receptor-positive (HR+) breast cancer, treatments that suppress ovarian function, combined with tamoxifen or the aromatase inhibitor exemestane, provide persistent reduction in the risk of recurrence compared to tamoxifen alone, long-term results of the IBCSG-led SOFT and TEXT clinical trials show. The findings, based on an average 12 to 13-year follow-up of patients in the trials, was presented at the 2021 San Antonio Breast Cancer Symposium.
The IBCSG-led international trials SOFT and TEXT are evaluating post-surgical hormone-blocking therapy in more than 5700 premenopausal women with early-stage, HR+ breast cancer. IBCSG had previously reported that, after 8 years of follow-up, ovarian suppression plus tamoxifen reduced the risk of breast cancer recurrence – and appeared to improve survival – more than tamoxifen alone. They also reported that ovarian suppression plus exemestane reduced recurrence to a greater extent than ovarian suppression plus tamoxifen, but without a further improvement in survival.
“The new findings indicate, after an average follow-up of more than 12 years, ovarian suppression plus tamoxifen or exemestane continues to lower the risk of recurrence more than tamoxifen alone for these patients,” says Meredith Regan, ScD, Director of the IBCSG Statistical and Data Management Center. Investigators also found that the reduction is greatest in patients using exemestane in conjunction with ovarian suppression.
“We continue to see that ovarian suppression reduces the risk of death long-term,” she continues. “In absolute terms, the reductions were more substantial for those at higher clinical risk – on the order of a 10% reduction in death at the 12-year follow-up point. We’re also seeing a later-emerging reduction in death with the use of exemestane and ovarian suppression vs. tamoxifen and ovarian suppression.”
She adds, “long-term follow up of these young women is quite important because of a continued risk of having a recurrence of their breast cancer even after 10 years. The IBCSG plans five more years of follow-up with these women.”


ETOP IBCSG Partners Foundation
Effingerstrasse 33
3008 Bern, Switzerland

Phone: +41 31 511 94 00

Member Login